報價延遲最少15分鐘:2025/11/18 12:15 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.285 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-9.37/0.78
|
|
企業價值
116.94M
|
| 資產負債 |
|
每股賬面淨值
7.50
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
19.89M
|
|
每股收益
0.13
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/18 12:15 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA. |
